

Massimo Marignani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6660490/publications.pdf>

Version: 2024-02-01

74
papers

2,180
citations

257357

24
h-index

243529

44
g-index

75
all docs

75
docs citations

75
times ranked

2845
citing authors

#	ARTICLE	IF	CITATIONS
1	Reversal of Iron Deficiency Anemia after <i>Helicobacter pylori</i> Eradication in Patients with Asymptomatic Gastritis. <i>Annals of Internal Medicine</i> , 1999, 131, 668.	2.0	176
2	Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease. <i>Archives of Internal Medicine</i> , 1999, 159, 1726.	4.3	147
3	A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1582-1591.	1.8	137
4	Reversal of Long-Standing Iron Deficiency Anaemia after Eradication of <i>Helicobacter pylori</i> Infection. <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 617-622.	0.6	127
5	Postbiotic Activities of Lactobacilli-derived Factors. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S18-S22.	1.1	118
6	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015, 61, 823-833.	3.6	109
7	High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia A prospective screening study. <i>American Journal of Gastroenterology</i> , 1999, 94, 766-772.	0.2	104
8	Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. <i>Gut</i> , 1998, 42, 792-794.	6.1	97
9	Atrophic Body Gastritis: Distinct Features Associated with <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 1997, 2, 57-64.	1.6	94
10	Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. <i>Annals of Hepatology</i> , 2017, 16, 107-114.	0.6	59
11	Association of Sarcopenia and Body Composition With Short-term Outcomes After Liver Resection for Malignant Tumors. <i>JAMA Surgery</i> , 2020, 155, e203336.	2.2	56
12	Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. <i>Future Oncology</i> , 2013, 9, 283-294.	1.1	54
13	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	1.6	54
14	Endocrine cell growths in atrophic body gastritis. Critical evaluation of a histological classification. , 1997, 182, 339-346.		48
15	Probiotics and the incidence of colorectal cancer: when evidence is not evident. <i>Digestive and Liver Disease</i> , 2006, 38, S277-S282.	0.4	46
16	Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. <i>World Journal of Hepatology</i> , 2011, 3, 278.	0.8	42
17	External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Hepatology</i> , 2018, 67, 2215-2225.	3.6	40
18	Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 677-683.	1.8	39

#	ARTICLE	IF	CITATIONS
19	HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. <i>Digestive and Liver Disease</i> , 2011, 43, 139-142.	0.4	38
20	Protective Role of Postbiotic Mediators Secreted by <i>Lactobacillus rhamnosus</i> GG Versus Lipopolysaccharide-induced Damage in Human Colonic Smooth Muscle Cells. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S140-S144.	1.1	38
21	Lansoprazole-induced microscopic colitis: An increasing problem? Results of a prospective case-series and systematic review of the literature. <i>Digestive and Liver Disease</i> , 2011, 43, 380-385.	0.4	37
22	Zollinger-Elison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1994, 8, 87-93.	1.9	35
23	Somatostatin Receptor Localization of Pancreatic Endocrine Tumors. <i>World Journal of Surgery</i> , 1996, 20, 241-244.	0.8	30
24	Nasogastric or nasointestinal feeding in severe acute pancreatitis. <i>World Journal of Gastroenterology</i> , 2010, 16, 3692.	1.4	28
25	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
26	Acute fulminant hepatitis E virus genotype 3e infection: Description of the first case in Europe. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 727-731.	1.5	21
27	Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients. <i>Digestive and Liver Disease</i> , 2002, 34, 270-278.	0.4	18
28	HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. <i>BMC Gastroenterology</i> , 2012, 12, 162.	0.8	18
29	Pancreatic-polypeptide cell hyperplasia associated with pancreatic or duodenal gastrinomas. <i>Human Pathology</i> , 1997, 28, 149-153.	1.1	17
30	Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. <i>Radiologia Medica</i> , 2013, 119, 367-76.	4.7	17
31	Hepatitis B in patients with hematological diseases: An update. <i>World Journal of Hepatology</i> , 2017, 9, 1043.	0.8	17
32	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017, 37, 1184-1192.	1.9	15
33	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
34	Long-term octreotide treatment of metastatic carcinoid tumor. <i>Annals of Oncology</i> , 2000, 11, 491-494.	0.6	14
35	Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules. <i>Clinical Imaging</i> , 2015, 39, 468-475.	0.8	14
36	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. <i>Liver International</i> , 2017, 37, 653-661.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 2564-2571.	0.6	12
38	Antral gastrin cell hyperfunction and Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 607-615.	1.9	11
39	Use and Safety Perception of Herbal Remedies in Patients With Liver/Biliary Tract Disorders. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, S54-S57.	1.1	10
40	Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1465-1473.	1.1	10
41	Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. <i>Viruses</i> , 2019, 11, 858.	1.5	9
42	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	1.0	9
43	Low influenza vaccination coverage in subjects with liver cirrhosis. An alert waiting for winter season 2020-2021 during the COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2021, 93, 2446-2452.	2.5	9
44	High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. <i>Gut and Liver</i> , 2020, 14, 357-367.	1.4	9
45	The prevalence of pancreatic cystic lesions in patients with liver cirrhosis is double that in controls. <i>United European Gastroenterology Journal</i> , 2017, 5, 1007-1014.	1.6	8
46	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251.	1.5	8
47	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , 2021, 13, 3810.	1.7	8
48	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 376-385.	0.6	7
49	Non-Hypervascular Hypointense Nodules at Gadoteric Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 302-310.	0.6	7
50	Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. <i>Microorganisms</i> , 2020, 8, 1792.	1.6	7
51	Patients with hematological malignancies and serological signs of prior resolved hepatitis B. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 37.	0.8	7
52	HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 46.	0.8	7
53	Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features. <i>Diagnostics</i> , 2021, 11, 956.	1.3	6
54	Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 750-752.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. <i>European Journal of Internal Medicine</i> , 2011, 22, 576-581.	1.0	5
56	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.4	5
57	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i> , hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020, 9, 928-939.	3.0	5
58	Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. <i>PLoS ONE</i> , 2014, 9, e110284.	1.1	5
59	Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study. <i>Current Therapeutic Research</i> , 1996, 57, 544-551.	0.5	4
60	Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). <i>International Journal of Molecular Medicine</i> , 2005, 15, 129.	1.8	4
61	Moyamoya disease as a possible cause of neurological impairment following liver transplantation for Wilson's disease. <i>Hepatology Research</i> , 2011, 41, 282-286.	1.8	4
62	Surveillance and Treatment Protocols to Detect and Treat Hepatitis B Virus Reactivation in Hepatitis B Surface Antigen-Negative/Antibody to Hepatitis B Core Antigen-Positive Patients Receiving Chemotherapy for Onco-Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2011, 29, e210-e210.	0.8	4
63	Anti-Helicobacter Pylori Therapy in Primary MALT Lymphoma of Rectum. <i>Tumori</i> , 2012, 98, e105-e110.	0.6	4
64	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	1.5	4
65	Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done. <i>Digestive and Liver Disease</i> , 2021, 53, 1315-1319.	0.4	4
66	Acute Infectious Diarrhea. <i>New England Journal of Medicine</i> , 2004, 350, 1576-1577.	13.9	3
67	Administration of Two Anti-TNF Agents in an Ulcerative Colitis Patient with HBV-related Cirrhosis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 430-431.	0.6	3
68	Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010035.	0.5	3
69	Elevated serum transaminases and celiac disease: possible modifications of a diagnostic algorithm. <i>Gastroenterology</i> , 2003, 125, 279-280.	0.6	2
70	Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?. <i>Annals of Hematology</i> , 2009, 88, 283-284.	0.8	2
71	Hepatocellular carcinoma in a non-cirrhotic liver of a HCV-positive woman with sustained viral response. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011050.	0.5	2
72	Les liaisons dangereuses™: Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2012, 3, 21.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Phenotype Expression in a Case of Adult Cystic Fibrosis Caused by an Extremely Rare Compound Heterozygous Genotype (2183AA>G/2789+5G>A). <i>Pancreas</i> , 2009, 38, 599-601.	0.5	1
74	Acute fulminant hepatitis E virus genotype 3e infection: description of the first case in Europe. <i>Infectious Diseases</i> , 2015, 47, 113-113.	1.4	0